“部长通道”再掀热潮 部委掌门人回应民生关切

Drug body to ease pain for foreign pharmaceutical firms
食药监局为国外医药企业开绿灯

There is a huge market potential for drugs and more foreign pharmaceutical companies should tap the sector, Bi Jingquan, chief of China Food and Drug Administration (CFDA), said on Sunday.
国家食品药品监督管理局局长毕井泉5日表示，医药行业的市场潜力巨大，应当对更多国外制药公司开放。

Bi said there are several reasons behind the shortage of new drugs in China, some of the causes are: Strict drug inspection and approval policies, shortage in drug inspection and approval personnel at the CFDA, and concerns from some foreign pharmaceutical companies over intellectual property protection in China, which make them reluctant to sell new drugs in the country.
毕井泉称，导致我国新药缺乏的原因有很多，其中一些因素包括：严格的药品审批政策、食药监局药品审批人员力量缺乏，还有一些国外制药公司因对我国知识产权保护有所担忧而不愿向我国出售新药。

The authorities will take measures such as streamlining approval procedures for drugs, intensify protection of intellectual property rights, and increase the staff for drug approval so that more new medicines are available in the market, he added.
毕井泉表示，政府将采取简化药物批准程序、加强知识产权保护以及增加审批人员力量等措施，以便于更多新药在国内上市。

英文来源：中国日报网
翻译&编辑：董静
审校：丹妮